Shortage of oral oseltamivir reported

The FDA warned clinicians about a temporary shortage of the oral suspension form of oseltamivir phosphate (Tamiflu) last week.

Due to increased demand, the manufacturer experienced delays in manufacturing the oral suspension of the drug (6 mg/mL; 60 mL). Additional supplies were expected to be available by mid-January, according to an FDA drug shortage posting.

In the interim, pediatric patients over 1 year of age can be dosed correctly using the 30-mg and 45-mg capsules of the drug. For patients who cannot swallow capsules, the capsules can be opened and the contents may be mixed with chocolate syrup or some other thick, sweet liquid, the FDA advised. Instructions for compounding a suspension are also available on the manufacturer's website.